Studies propose the connection between Nrf2 and NF-κΒ, and targeting these factors can be considered effective for increasing the survival rate of patients with APL and their response to chemotherapy and other leukemia. This evidence concerns the gene NFE2L2 and acute promyelocytic leukemia.